Vol 13, No 3 (June 30, 2024): Chinese Clinical Oncology

Identification of most representative hub-genes for diagnosis, prognosis, and therapies of hepatocellular carcinoma

TPD52 is a prognostic biomarker and potential therapeutic target for ER⁺/PR⁺/HER2⁺ breast cancer

SZC010 suppresses breast cancer development by regulating the PI3K/Akt/NF-κB signaling pathway

Clinical analysis of patients with skin metastasis of cervical squamous cell carcinoma

Immunotherapy for patients with thyroid cancer: a comprehensive appraisal

Discrepancy between recommendations regarding hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer management: a narrative review

Updates in the role of the tumor microenvironment cellular crosstalk and genetic signatures in diffuse large B-cell lymphoma: a narrative review

Metformin as a therapeutic tool for resistant hematological malignancies: a literature review

Safety and tolerability of radiotherapy in combination with systemic targeted therapies for treatment of hepatocellular carcinoma: a narrative review

Update on management of pancreatic cancer: a literature review

Paraneoplastic leukocytosis secondary to carcinosarcoma: a report of two cases and literature review

A case of pulmonary tuberculosis that developed during nivolumab and ipilimumab treatment for pulmonary adenocarcinoma that recurred two months after completion of anti-tuberculous treatment

Combining cabozantinib, nivolumab and ipilimumab in advanced hepatocellular carcinoma: does benefit outweigh toxicity?

The impressive efficacy of anti-G protein-coupled receptor, class C group 5 member D chimeric antigen receptor T cells in patients with relapsed or refractory multiple myeloma

European Society of Medical Oncology (ESMO) guidelines for oncogene-addicted metastatic non-small cell lung cancer (NSCLC): a personalized treatment for each patient